Afabicin diolamine in Renal Insufficiency: NCT07758608 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
60
Planned enrollment
2027-12-01
Primary-completion proxy
Executive view
NCT07758608 evaluates Afabicin diolamine in Renal Insufficiency. The disclosed sponsor is Debiopharm International SA, the design is Interventional, and the geographic footprint is Germany. The first listed primary endpoint is Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Afabicin Desphosphono, assessed over From predose and at multiple timepoints (up to Day 5) post dose.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07758608 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Renal Insufficiency landscape. Drug & Asset MCP drug_fetch was queried for Afabicin diolamine, while Company & Deal Intelligence MCP organization_fetch was queried for Debiopharm International SA.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07758608 | Afabicin diolamine | Phase 1 / Not yet recruiting | Debiopharm International SA | Germany | Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Afabicin Desphosphono From predose and at multiple timepoints (up to Day 5) post dose | 2027-12-01 |
| NCT07786571 | Dorzagliatin | Not Applicable / Not yet recruiting | Sun Yat-Sen University | China | Change in Time in Range (TIR, 3.9-10.0 mmol/L) from baseline to Week 14 Baseline to Week 14 | 2029-03-01 |
| NCT07784452 | Recombinant meningococcal group B vaccine (Sanroad Biological Products) | Not Applicable / Completed | Jinnah Hospital Lahore | Pakistan | Proportion of Participants Achieving Seroprotection (Anti-HBs Titer ≥10 mIU/mL) 30 days after completion of the assigned vaccination schedule (Month… | 2026-07-20 |
| NCT07786168 | Roxadustat | Not Applicable / Completed | Shaikh Zayed Hospital | Pakistan | Change in Hemoglobin Level From Baseline to 3 Months Baseline to 3 months | 2026-06-20 |
| NCT07781020 | Mecobalamin | Not Applicable / Completed | Jinnah Hospital Lahore | Pakistan | Change in Serum Vitamin B12 Level from Baseline to Week 5 Baseline and Week 5 (one week after completion of the 4-week interven… | 2026-05-22 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07758608 is a Phase 1, not yet recruiting study with 60 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Afabicin Desphosphono” over “From predose and at multiple timepoints (up to Day 5) post dose.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 60 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Afabicin diolamine as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Renal Insufficiency. These records do not establish direct evidence for NCT07758608 unless the registration number matches.
Hydroxychloroquine for the Management of CVD in CKD
Phase 2; n=100; Baseline(Mean) = 1674.38 mm3 (Standard Deviation, 439.89); Baseline(Mean) = 1498.57 mm3 (Standard Deviation, 341.54) Source: https://clinicaltrials.gov/ct2/show/results/NCT03636152
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C…
Phase 2; n=143; Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median) = -14.8 Time-Averaged Percent Change in hsCRP (Inter-Quartile Range, -35.8 to 17.4); Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90(Median): Median Difference (Net) = -59.817(95% CI, -79.690 to -39.943), P-Value = <0.0001; Median Difference (Net)… Source: https://clinicaltrials.gov/ct2/show/results/NCT06362759
Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent…
Phase 3; n=211; EFFICACY: MATE-3 Score(Mean) = 0.9 Scores on a scale (Standard Deviation, 2.2); EFFICACY: MATE-3 Score(Mean): Mean Difference (Net) = -0.32(95% CI, -0.90 to 0.20), P-Value = 0.16 Source: https://clinicaltrials.gov/ct2/show/results/NCT03386539
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Afabicin diolamine is indexed as Small molecule drug with MECR biology and a global stage of Phase 2. The asset profile lists GSK Plc as an originator or developer.
Debiopharm International SA is indexed in Switzerland with the website https://www.debiopharm.com. Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug. The record lists 26 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Afabicin diolamine is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07758608
Protocol source: https://clinicaltrials.gov/study/NCT07758608
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Afabicin diolamine in Renal Insufficiency is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Afabicin Desphosphono and 2027-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
